Edition:
United States

Pfizer Inc (PFE)

PFE on New York Consolidated

43.43USD
15 Oct 2018
Change (% chg)

$-0.35 (-0.80%)
Prev Close
$43.78
Open
$43.65
Day's High
$43.71
Day's Low
$42.98
Volume
12,913,818
Avg. Vol
20,242,753
52-wk High
$45.81
52-wk Low
$33.20

Latest Key Developments (Source: Significant Developments)

Pfizer Inc Says Board Approved New Compensation Arrangements For Albert Bourla
Monday, 1 Oct 2018 05:03pm EDT 

Oct 1 (Reuters) - Pfizer Inc ::PFIZER INC - BOARD APPROVED NEW COMPENSATION ARRANGEMENTS FOR ALBERT BOURLA INCLUDING INCREASE IN HIS ANNUAL BASE SALARY FROM $1.4 MILLION TO $1.6 MILLION.PFIZER INC - BOARD APPROVED NEW COMPENSATION FOR IAN READ IN HIS ROLE AS EXECUTIVE CHAIRMAN AN ANNUAL BASE SALARY OF $1.2 MILLION.PFIZER INC - NEW COMPENSATIONS FOR BOURLA & READ ARE EFFECTIVE FROM JANUARY 1, 2019 WHEN THEY GET INTO THEIR NEW ROLES.  Full Article

Pfizer Granted FDA Breakthrough Therapy Designation For 20-Valent Pneumococcal Conjugate Vaccine
Thursday, 20 Sep 2018 08:00am EDT 

Sept 20 (Reuters) - Pfizer Inc ::PFIZER GRANTED FDA BREAKTHROUGH THERAPY DESIGNATION FOR 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE FOR THE PREVENTION OF INVASIVE DISEASE AND PNEUMONIA IN ADULTS AGED 18 YEARS AND OLDER.PFIZER INC - PFIZER EXPECTS TO START PHASE 3 TRIALS IN A FEW MONTHS.PFIZER INC - 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (20VPNC) CANDIDATE, PF-06482077, RECEIVED BREAKTHROUGH THERAPY DESIGNATION FROM US FDA.  Full Article

Pfizer Receives Breakthrough Therapy Designation From FDA For Pf-06651600, An Oral Jak3 Inhibitor, For The Treatment Of Patients With Alopecia Areata
Wednesday, 5 Sep 2018 08:50am EDT 

Sept 5 (Reuters) - Pfizer Inc ::PFIZER RECEIVES BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR PF-06651600, AN ORAL JAK3 INHIBITOR, FOR THE TREATMENT OF PATIENTS WITH ALOPECIA AREATA.PFIZER INC - PHASE II DATA ACCEPTED FOR LATE-BREAKER NEWS SESSION AT 2018 EADV CONGRESS.PFIZER INC - PFIZER IS ALSO WORKING WITH EUROPEAN MEDICINES AGENCY (EMA) ON CLINICAL DEVELOPMENT PROGRAM FOR PF-06651600.  Full Article

Pfizer And Astellas Amend Clinical Research Protocols For Two Phase 3 Trials Of Enzalutamide
Wednesday, 22 Aug 2018 05:00pm EDT 

Aug 22 (Reuters) - Astellas Pharma Inc <4503.T>::PFIZER AND ASTELLAS AMEND CLINICAL RESEARCH PROTOCOLS FOR TWO PHASE 3 TRIALS OF ENZALUTAMIDE IN PATIENTS WITH HORMONE-SENSITIVE PROSTATE CANCER.PFIZER INC - AMENDMENTS ACCELERATE ANTICIPATED PRIMARY COMPLETION DATES FOR BOTH ARCHES AND EMBARK TRIALS.PFIZER INC - AMENDMENTS TO PROTOCOLS FOR TWO REGISTRATIONAL PHASE 3 TRIALS, ARCHES AND EMBARK.PFIZER INC - CHANGES TO PROTOCOL FOR PHASE 3 ARCHES STUDY INCLUDE REVISION OF PLANNED ANALYSES OF PRIMARY AND SECONDARY ENDPOINTS.PFIZER INC - COS ANTICIPATE PRIMARY COMPLETION DATE FOR ARCHES CLINICAL TRIAL TO BE IN LATE 2018.PFIZER INC - ESTIMATED PRIMARY COMPLETION DATE FOR EMBARK CLINICAL TRIAL IS MID-2020.PFIZER INC - REVISIONS WERE ALSO MADE TO PROTOCOL FOR PHASE 3 EMBARK STUDY.PFIZER - MAIN PURPOSE OF AMENDMENT TO PROTOCOL FOR PHASE 3 EMBARK STUDY IS TO REVISE THE PLANNED ANALYSES OF THE PRIMARY & SEVERAL SECONDARY ENDPOINTS.  Full Article

Exact Sciences Says Enter Agreement Through 2021 With Pfizer To Co-Promote Cologuard
Wednesday, 22 Aug 2018 12:08pm EDT 

Aug 22 (Reuters) - Exact Sciences Corp ::EXACT SCIENCES SAYS CO, PFIZER ENTER INTO AGREEMENT THROUGH 2021 TO CO-PROMOTE COLOGUARD, A STOOL DNA SCREENING TEST FOR COLORECTAL CANCER.EXACT SCIENCES SAYS AS PER AGREEMENT, PFIZER WILL CO-PROMOTE COLOGUARD WITH CO BEGINNING IN Q4 2018.EXACT SCIENCES SAYS AS PER AGREEMENT, CO WILL MAINTAIN RESPONSIBILITY FOR ALL ASPECTS OF MANUFACTURING & LABORATORY OPERATIONS OF COLOGUARD.EXACT SCIENCES SAYS AS PER AGREEMENT, PFIZER WILL SHARE GROSS PROFITS & MARKETING EXPENSES EQUALLY ABOVE AN AGREED UPON BASELINE.  Full Article

Pfizer Inc, In July 2018, DOJ Requested Documents Related To Contracts With Iraqi Ministry Of Health, Which Co Will Be Providing
Thursday, 9 Aug 2018 04:44pm EDT 

Aug 9 (Reuters) - Pfizer Inc ::PFIZER INC - IN JULY 2018, DOJ REQUESTED DOCUMENTS RELATED TO CONTRACTS WITH IRAQI MINISTRY OF HEALTH, WHICH CO WILL BE PROVIDING.  Full Article

U.S. FDA Grants Priority Review For Pfizer's NDA For Glasdegib
Wednesday, 27 Jun 2018 08:00am EDT 

June 27 (Reuters) - Pfizer Inc ::U.S. FDA GRANTS PRIORITY REVIEW FOR PFIZER’S NEW DRUG APPLICATION FOR GLASDEGIB IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA.PFIZER INC - PRESCRIPTION DRUG USER FEE ACT (PDUFA) GOAL DATE FOR A DECISION BY FDA IS IN DECEMBER 2018.  Full Article

ACCC Seeks Special Leave To Appeal Full Federal Court's Pfizer Australia Pty Judgment
Monday, 25 Jun 2018 02:59am EDT 

June 25 (Reuters) - AUSTRALIAN COMPETITION & CONSUMER COMMISSION::SEEKS SPECIAL LEAVE TO APPEAL FULL FEDERAL COURT’S PFIZER AUSTRALIA PTY JUDGMENT.  Full Article

IBT Urges Pfizer Shareholders To Vote For Proposal 7 For Corporate Political Spending Disclosure
Wednesday, 18 Apr 2018 06:12am EDT 

April 18 (Reuters) - Pfizer Inc ::INTERNATIONAL BROTHERHOOD OF TEAMSTERS - URGES PFIZER SHAREHOLDERS TO VOTE FOR PROPOSAL 7 FOR CORPORATE POLITICAL SPENDING DISCLOSURE.  Full Article

Pfizer Will Relocate Its Global Headquarters From 235 East 42nd Street To Spiral
Tuesday, 10 Apr 2018 08:30am EDT 

April 10 (Reuters) - Pfizer Inc ::PFIZER SIGNS LEASE FOR THE SPIRAL AT HUDSON YARDS IN MANHATTAN.CURRENTLY IN PROCESS OF SELLING ITS HEADQUARTERS PROPERTY ON EAST 42(ND) STREET.PFIZER INC - AS PART OF 20-YEAR LEASE AGREEMENT, PFIZER WILL RELOCATE ITS GLOBAL HEADQUARTERS FROM 235 EAST 42ND STREET TO SPIRAL.YEAR LEASE FOR SPIRAL, AN OFFICE TOWER BEING BUILT BY TISHMAN SPEYER, AT 66 HUDSON BOULEVARD AT HUDSON YARDS OF MANHATTAN.  Full Article

Pfizer hit with multi-plaintiff suit over anti-seizure drug Dilantin

Pfizer Inc has been sued by 10 people alleging the company and its subsidiaries failed to warn of the risk of severe brain damage from its anti-seizure medication Dilantin.